Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP   US8649091068

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/24/2015 02/25/2015 02/26/2015 02/27/2015 03/02/2015 Date
15.57(c) 15.69(c) 16(c) 15.38(c) 13.6(c) Last
243 389 146 629 188 875 263 104 701 541 Volume
+2.84% +0.77% +1.98% -3.88% -11.57% Change
More quotes
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs based on prostones and other novel drug technologies.Prostones are naturally occurring fatty acid metabolites with unique physiological... 
Sector
Biotechnology & Medical Research
Calendar
03/02 | 01:30pmPresentation
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 115 M
EBIT 2014 31,3 M
Net income 2014 12,4 M
Finance 2014 13,8 M
Yield 2014 -
Sales 2015 133 M
EBIT 2015 44,9 M
Net income 2015 24,1 M
Finance 2015 59,9 M
Yield 2015 -
PER 2014 64,98
PER 2015 29,47
EV / Sales 2014 5,82x
EV / Sales 2015 4,66x
Capitalization 682 M
More Financials
Latest news on SUCAMPO PHARMACEUTICALS, I
02/23 SUCAMPO PHARMACEUTICALS : Regulation FD Disclosure, Financial Statements and Exh..
02/22 Sucampo Announces Webcast of Its Presentation at the 2015 Cowen and Company H..
02/18 Sucampo Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2014 Ear..
02/11 Sucampo Announces Resolution of Par Pharmaceutical's ANDA for RESCULA(R)
02/05 Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2015 Lee..
01/31 SUCAMPO PHARMACEUTICALS : Appoints Andrew Smith, FCMA, CGMA as CFO
01/30 Sucampo Appoints Andrew Smith, FCMA, CGMA as CFO
01/30 AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommenda..
More news
Sector news Bio Therapeutic Drugs
06:18p PUMA BIOTECHNOLOGY : Biotech reports 4Q loss
04:17p PUMA BIOTECHNOLOGY : Reports Fourth Quarter and Full Year 2014 Financial Results
08:22a ACTELION : Selexipag (Uptravi) data in pulmonary arterial hypertension to be pre..
Plus d'actualités du secteur Bio Therapeutic Drugs


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF